Cargando…

Benefit/risk profile of dapagliflozin 5 mg in the DEPICT‐1 and ‐2 trials in individuals with type 1 diabetes and body mass index ≥27 kg/m(2)

AIM: The DEPICT‐1 and ‐2 studies (NCT02268214, NCT02460978) evaluated the efficacy and safety of dapagliflozin in individuals with type 1 diabetes who were receiving intensive insulin therapy. The DEPICT‐1 and ‐2 studies (NCT02268214, NCT02460978) evaluated the efficacy and safety of dapagliflozin i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathieu, Chantal, Dandona, Paresh, Birkenfeld, Andreas L, Hansen, Troels Krarup, Iqbal, Nayyar, Xu, John, Repetto, Enrico, Scheerer, Markus Florian, Thoren, Fredrik, Phillip, Moshe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693058/ https://www.ncbi.nlm.nih.gov/pubmed/32691513 http://dx.doi.org/10.1111/dom.14144

Ejemplares similares

SAT-LB025 Analysis of Benefit/Risk in the Subgroup of Patients with BMI of >=27 Kg/m(2) in the Dapagliflozin DEPICT-1 and -2 Trials in Type 1 Diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT‐2 study): 52‐week results from a randomized controlled trial
por: Mathieu, Chantal, et al.
Publicado: (2020)

Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT‐1 and ‐2 studies
por: Phillip, Moshe, et al.
Publicado: (2020)

Long‐term (52‐week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT‐2 study
por: Araki, Eiichi, et al.
Publicado: (2021)

Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme
por: Gordon, Jason, et al.
Publicado: (2020)

LBSUN213 An Investigation Into The Effects Of Dapagliflozin On Ketogenesis In Type 1 Diabetes
por: Ghanim, Husam, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT‐5): 52‐week results from a randomized, open‐label, phase III clinical trial
por: Araki, Eiichi, et al.
Publicado: (2019)

Comparison of the initial and residual speed of Ixodes scapularis kill on dogs treated with a single dose of Bravecto(®) Chew (25 mg/kg fluralaner) or Simparica TRIO(®) (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)
por: Reif, Kathryn E., et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes
por: Watada, Hirotaka, et al.
Publicado: (2018)

Modified electroconvulsive therapy in a resource-challenged setting: Comparison of two doses (0.5 mg/kg and 1 mg/kg) of suxamethonium chloride
por: Aaron, Olurotimi I., et al.
Publicado: (2020)

Comparison of the anesthetic effects between 5 mg/kg of alfaxalone and 10 mg/kg of propofol administered intravenously in cats
por: TAMURA, Jun, et al.
Publicado: (2021)

Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes
por: Aberle, Jens, et al.
Publicado: (2020)

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg(−1) rifampicin
por: te Brake, Lindsey H.M., et al.
Publicado: (2021)

Comparative analysis of efficacy of lignocaine 1.5 mg/kg and two different doses of dexmedetomidine (0.5 μg/kg and 1 μg/kg) in attenuating the hemodynamic pressure response to laryngoscopy and intubation
por: Gulabani, Michell, et al.
Publicado: (2015)

What is the easier and more reliable dose calculation for iv Phenytoin in children at risk of developing convulsive status epilepticus, 18 mg/kg or 20 mg/kg?
por: Prasad, Manish, et al.
Publicado: (2013)

Randomized Single-Blinded Non-inferiority Trial Of 7 mg/kg Pentamidine Isethionate Versus 4 mg/kg Pentamidine Isethionate for Cutaneous Leishmaniaisis in Suriname
por: Hu, Ricardo V. P. F., et al.
Publicado: (2015)

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire
por: Tarhini, Ahmad, et al.
Publicado: (2018)

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
por: Ascierto, Paolo Antonio, et al.
Publicado: (2020)

Correction: Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Publicado: (2020)

Comparing the frequency of isotretinoin-induced hair loss at <0.5-mg/kg/d versus ≥0.5-mg/kg/d dosing in acne patients: A systematic review
por: Lytvyn, Yuliya, et al.
Publicado: (2022)

Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia
por: Taher, Ali, et al.
Publicado: (2011)

Minimizing Glycemic Fluctuations in Patients with Type 2 Diabetes: Approaches and Importance
por: Dandona, Paresh
Publicado: (2017)

Efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2014)

A Multicentre Randomized Controlled Trial of the Efficacy and Safety of Single-Dose Praziquantel at 40 mg/kg vs. 60 mg/kg for Treating Intestinal Schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil
por: Olliaro, Piero L., et al.
Publicado: (2011)

Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study
por: Scheerer, Markus F, et al.
Publicado: (2016)

A 27-kg mucinous cystadenoma of the ovary presenting with deep vein thrombosis
por: Tola, Esra Nur, et al.
Publicado: (2016)

Residual paralysis caused by 50 mg rocuronium after reversal with 4 mg/kg sugammadex: a case report
por: Uzawa, Kohji, et al.
Publicado: (2021)

Is the rapid sequence induction possible with 0.6 mg/kg rocuronium in pediatric patient?
por: Lee, Sang Kyu, et al.
Publicado: (2010)

Sodium‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
por: Dandona, Paresh, et al.
Publicado: (2017)

Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
por: Gastaldelli, Amalia, et al.
Publicado: (2019)

Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: Phase 1b study
por: Miller, Robert Scott, et al.
Publicado: (2012)

Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
por: Neslusan, Cheryl, et al.
Publicado: (2018)

Safety and Efficacy of 4 mg·kg(−1) Sugammadex for Simultaneous Pancreas-Kidney Transplantation Recipients: A Prospective Randomized Trial
por: Tang, Jiancheng, et al.
Publicado: (2023)

Serum levels of vancomycin: is there a prediction using doses in mg/kg/day or m(2)/day for neonates?
por: Romanelli, Roberta Maia de Castro, et al.
Publicado: (2016)

RanDepict: Random chemical structure depiction generator
por: Brinkhaus, Henning Otto, et al.
Publicado: (2022)

The abscopal effect: efficacy of radiotherapy in patients on progression after treatment with ipilimumab 3 mg/kg
por: Grimaldi, Antonio M, et al.
Publicado: (2013)

Effects of 3 mg/kg Body Mass of Caffeine on the Performance of Jiu-Jitsu Elite Athletes
por: Merino-Fernández, María, et al.
Publicado: (2022)

Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia
por: Tamiru, Aschalew, et al.
Publicado: (2021)

P1080: COMPARISON OF NIVOLUMAB 40 MG EFFICACY VERSUS 3 MG/KG IN PATIENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Fedorova, L., et al.
Publicado: (2022)

Benefit‐risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers
por: Bei, Di, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5bcdjpfhkph3p71658ufg4vpq6